RxDoctor Payments Data

Jewell Carr, MD

Family Medicine · Charlotte, NCNPI 1487970265

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,598 of the $2,902 with a category attached, or 89.5%. Eli Lilly accounts for 94.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $2,738 and has fallen 94.8% since, to $142 in 2025.

$2,902in general payments, 2019–2025

Across 15 payments — averaging $193.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3K
  • GSK$142
  • Novo Nordisk$21
$162,744in research payments, 2019–2025

Across 14 payments — averaging $11,625 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$160K
  • GSK$2K

What the payments were for

  • Travel & lodging$2,59890%
  • Food & beverage$30410%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly12$2,738
GSK2$142
Novo Nordisk1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,902 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$3,947
Medicare patients
20
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide26$27,844
OzempicSemaglutide20$18,426
EliquisApixaban11$6,452
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$4,022
SymbicortBudesonide/Formoterol Fumarate17$4,006
Diclofenac Sodium16$1,496
Gabapentin55$954
Albuterol Sulfate HfaAlbuterol Sulfate36$807
Omeprazole29$686
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen29$640
Fluticasone Propionate38$496
Atorvastatin Calcium45$374
Esomeprazole Magnesium17$336
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$312
Montelukast Sodium30$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21$18,42620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →